Get started
Author

Rocío Montero‐Vallejo

Observed names: Montero-Vallejo, Rocío, R Montero Vallejo, R. Montero-Vallejo, Rocio Montero-Vallejo, Roció Montero-Vallejo, Rocío Montero-Vallejo
Observed institutions: Linköping University, Consejo Superior de Investigaciones Científicas, Medical University of South Carolina, Andalusian Health Service, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Biomedicina de Sevilla, Nordic Bioscience (Denmark), Hospital Universitario Virgen del Rocío, Universidad de Sevilla
ORCID: 0000-0001-8510-9512
Observed ORCID: 0000-0001-8510-9512
OpenAlex ID: A5003305666
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis
2021 · Emmanuel Anandraj Selvaraj, Ferenc Emil Mózes, et al. · Journal of Hepatology · 402
PDF
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
2024 · Michele Vacca, Ioannis Kamzolas, et al. · Nature Metabolism · 278
PDF
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
2023 · Ferenc E Mózes, Jenny A Lee, et al. · The Lancet. Gastroenterology & hepatology · 241
PDF
miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
2018 · Chang-Hai Liu, Javier Ampuero, et al. · Journal of Hepatology · 197
PDF
Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation
2022 · Rocío Gallego-Durán, Javier Ampuero, et al. · Scientific Reports · 59
Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function
2021 · Natália da Silva Lima, Marcos F. Fondevila, et al. · Journal of Hepatology · 46
PDF
Fibroblast growth factor 21 is a hepatokine involved in MASLD progression
2024 · Rocío Gallego‐Durán, Javier Ampuero, et al. · United European Gastroenterology Journal · 40
Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study
2020 · Rocío Muñoz-Hernández, Javier Ampuero, et al. · Clinical and Translational Gastroenterology · 37
Long non‐coding RNA H19 as a biomarker for hepatocellular carcinoma
2022 · Ángela Rojas, Antonio Gil‐Gómez, et al. · Liver International · 34
Novel insights into metabolic‐associated steatotic liver disease preclinical models
2024 · Rocío Montero‐Vallejo, Douglas Maya‐Miles, et al. · Liver International · 14
PDF
Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases
2021 · Rocío Gallego-Durán, Rocío Montero-Vallejo, et al. · Frontiers in Immunology · 13
PDF
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study
2026 · Michael Pavlides, Yasaman Vali, et al. · Nature Medicine · 11
PDF
Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients
2022 · Antonio Gil-Gómez, Ángela Rojas, et al. · International Journal of Molecular Sciences · 11
Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome
2024 · Sheila Gato, Vanessa García-Fernández, et al. · European Cardiology Review · 9
Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool
2022 · Patricia Marañón, Carlos Ernesto Fernández-García, et al. · Biomarker Research · 9
Role of EpCAM + CD133 + extracellular vesicles in steatosis to steatohepatitis transition in NAFLD
2023 · Rocío Muñoz‐Hernández, Sheila Gato, et al. · Liver International · 7
PDF
Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models
2019 · Rocío Gallego-Durán, Leticia Álvarez-Amor, et al. · Revista Española de Enfermedades Digestivas · 5
Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis
2023 · Patricia Marañón, Stephania C. Isaza, et al. · Biomarker Research · 4
PDF
Circulating PCSK9 levels are correlated with advanced disease in patients with biopsy-proven non-alcoholic fatty liver disease.
2021 · R. Muñoz-Hernández, S. Gato, et al. · Atherosclerosis · 1
Genetic and functional analysis of FGF21 in NAFLD/NASH
2018 · R. Gallego-Durán, F. Martin, et al. · Journal of Hepatology · 1
Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study
2026 · Yasaman Vali, Kristy Wonders, et al. · The Lancet
WED-153 Accuracy of non-invasive tests for ruling out or in advanced fibrosis in MASLD patients across clinical settings: a systematic review and meta-analysis
2026 · Douglas Maya-Miles, Evangelia Mentsiou-Nikolaou, et al. · Journal of Hepatology
THU-287 Dysregulation of ureagenesis and glutaminolysis in DIAMONDTM mice played a major role in MASLD progression
2024 · Rocío Gallego-Durán, Douglas Maya, et al. · Journal of Hepatology
THU-296 Identification and assessment of new circulating serological biomarkers for the evaluation of liver disease severity in MASLD patients
2024 · Douglas Maya, Rocío Gallego-Durán, et al. · Journal of Hepatology
FRI-501 Platelet-derived extracellular vesicles (PEVs) as a potential biomarker for hepatocellular carcinoma (HCC)
2024 · Ángela Rojas, Rocío Munoz-Hernández, et al. · Journal of Hepatology
Works count: 46
Citation count: 1,419
H-index: 11
I10-index: 13
Year
Topic
Type